Compass Therapeutics, Inc. (CMPX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Question-and-Answer SessionAnd I was looking at your stock price year-to-date, up 290%. I mean that's quite impressive compared to XBI of 30%. So the company is clearly doing something right. Can you tell us -- maybe we start off with the two clinical stage programs. And if you could maybe provide us an overview of both programs, target indications and then we can dig in a little bit more.Thomas SchuetzCEO & Vice Chairman Sure. Yes, I think to your first point, I think it might be related to our high-qualit ...